Back

Inflammatory endothelial cells promote infiltration of antigen-licensed cytotoxic T cells in malignant gliomas after irradiation

Tejido, C.; Grassl, N.; Elmadany, N.; Rosenbauer, J.; Zaira, S.; Sanghvi, K.; Agardy, D. A.; Sinn, R.; Bunse, T.; Mathioudaki, A.; Jaehne, K.; Sonner, J. K.; Breckwoldt, M. O.; Suwala, A. K.; Gerstung, M.; Sahm, F.; Bunse, L.; Platten, M. G.; Sahm, K.

2026-07-13 immunology
10.64898/2026.07.08.737259 bioRxiv
Show abstract

Insufficient T cell infiltration into malignant gliomas fundamentally limits the efficacy of adoptive T cell therapy. Here we show that fractionated irradiation overcomes this barrier by reprogramming the tumor endothelium towards an immune-recruiting interface. Using complementary murine glioma models combined with adoptive T cell transfer, antigen-specific vaccination, and single-cell transcriptomic and T cell receptor profiling, we demonstrate that irradiation enhances the accumulation, clonal expansion, and effector differentiation of tumor-specific CD8+ T cells. Irradiated tumors showed increased T cell receptor clonality and local enrichment of proliferative effector CD8 T cells with enhanced cytotoxic, interferon-responsive, and oxidative metabolic programs. Mechanistically, irradiation triggers a conserved interferon-driven endothelial program marked by antigen presentation and upregulation of adhesion molecules, including ICAM-1 and VCAM-1. This radiation-induced endothelial activation program preferentially seen in inflammatory endothelial subsets was conserved in human glioblastoma and linked to T cell recruitment and maintenance of activated CD8 T cell states. Functionally, irradiation synergized with adoptive T cell transfer and antigen-specific vaccination to promote glioma-specific T cell accumulation and effector differentiation, improving tumor control and survival. Together, these findings identify radiation-induced endothelial activation as a key regulator of T cell trafficking across the brain tumor vasculature highlighting the vascular niche as a critical determinant of immunotherapy efficacy and a rational target for combination strategies in glioblastoma.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Journal for ImmunoTherapy of Cancer
75 papers in training set
Top 0.1%
14.8%
2
Nature Communications
5641 papers in training set
Top 16%
11.7%
3
Neuro-Oncology
36 papers in training set
Top 0.1%
11.7%
4
Cell Reports
1498 papers in training set
Top 6%
6.1%
5
Science Translational Medicine
127 papers in training set
Top 0.4%
4.8%
6
Nature Immunology
79 papers in training set
Top 0.6%
4.8%
50% of probability mass above
7
Journal of Clinical Investigation
179 papers in training set
Top 0.9%
4.4%
8
JCI Insight
277 papers in training set
Top 2%
3.2%
9
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 17%
3.2%
10
Cancer Cell
42 papers in training set
Top 0.6%
2.4%
11
eLife
5828 papers in training set
Top 42%
2.3%
12
Molecular Therapy
81 papers in training set
Top 0.7%
2.3%
13
Cell Reports Medicine
153 papers in training set
Top 2%
2.1%
14
Immunity
67 papers in training set
Top 0.9%
2.1%
15
Journal of Experimental Medicine
119 papers in training set
Top 1%
1.9%
16
Science Advances
1243 papers in training set
Top 23%
1.3%
17
Cancer Research
130 papers in training set
Top 2%
1.3%
18
The EMBO Journal
309 papers in training set
Top 4%
1.3%
19
International Journal of Radiation Oncology*Biology*Physics
25 papers in training set
Top 0.4%
1.1%
20
Theranostics
37 papers in training set
Top 1.0%
0.9%
21
Cancer Immunology Research
35 papers in training set
Top 0.9%
0.8%
22
Science Immunology
88 papers in training set
Top 2%
0.8%
23
Advanced Science
286 papers in training set
Top 10%
0.8%
24
EMBO Reports
263 papers in training set
Top 9%
0.6%
25
Cell Death & Disease
21 papers in training set
Top 0.6%
0.6%
26
Cancer Letters
35 papers in training set
Top 1%
0.6%